Pharmaceuticals company Neuland Laboratories announced Q2FY26 results Total Income: Rs 516.1 crore compared to Rs 315.2 crore during Q2FY25, change 63.70%. EBITDA: Rs 156.9 crore compared to Rs 65.7 crore during Q2FY25, change 138.80%. EBITDA Margin: 30.40% for Q2FY26. PBT: Rs 129.0 crore compared to Rs 48.5 crore during Q2FY25, change 166.60%. PAT: Rs 96.5 crore compared to Rs 32.0 crore during Q2FY25, change 201.60%. Sucheth Davuluri, Vice-Chairman & Chief Executive Officer, said: “The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.” Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.” Result PDF
Pharmaceuticals company Neuland Laboratories announced Q1FY26 results Total Income: Rs 300.6 crore compared to Rs 444.4 crore during Q1FY25, change -32.40%. EBITDA: Rs 42.1 crore compared to Rs 128.6 crore during Q1FY25, change -67.30%. EBITDA Margin: 14.00% for Q1FY26. PBT: Rs 17.4 crore compared to Rs 130.3 crore during Q1FY25, change -86.80%. PAT: Rs 13.7 crore compared to Rs 98.3 crore during Q1FY25, change -86.10%. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer, said: “While Q1FY26 has been below par as a result of the flow of customer orders, it doesn’t change our outlook on the healthy growth that we anticipate this financial year. The investments we have announced are proceeding according to plan and would be drivers of short as well as long term growth. We continue to focus on cost optimization opportunities across products and processes which will enable us to further strengthen our position in key products.” Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “We see substantial growth this year from our commercial molecules even as there is a significant influx of new business from existing and new customers along with customers’ pipeline projects making exciting progress. Given customers’ interest and evolving expectations we are continuing to invest in our people and capabilities which should see Neuland further differentiated as a CDMO with deep expertise as well as an agile innovative partner.” Result PDF
Conference Call with Neuland Laboratories Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Neuland Laboratories announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total Income: Rs 335.8 crore vs. Rs 390.4 crore — down 14.0% EBITDA: Rs 58.2 crore vs. Rs 112.2 crore — down 48.1% EBITDA Margin %: 17.3% vs. 28.7% — contracted by 1140 bps PAT: Rs 27.7 crore vs. Rs 67.6 crore — down 59.0% PAT Margin %: 8.3% vs. 17.3% — contracted by 900 bps EPS (Basic): Rs 21.6 vs. Rs 52.7 — down 59.0% FY25 Financial Highlights: Total Income: Rs 1,497.3 crore vs. Rs 1,571.1 crore — down 4.7% EBITDA: Rs 342.8 crore vs. Rs 474.5 crore — down 27.7% EBITDA Margin %: 22.9% vs. 30.2% — contracted by 730 bps PAT: Rs 259.4 crore vs. Rs 299.6 crore — down 13.4% PAT Margin %: 17.3% vs. 19.1% — contracted by 180 bps EPS (Basic): Rs 202.2 vs. Rs 233.5 — down 13.4% Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We saw marginal decrease in topline in FY25 as compared to FY24. which is further reflected in terms of the decline in operating margins. Nevertheless, these results are in line with our initial outlook at the start of the year regarding our expectations for FY25. During the course of the year we have committed to making investments which will significantly drive our growth in the medium and long term. Neuland continues to be recognized for its capabilities and quality track record, and we have good visibility on short and long term growth” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “The CMS revenues of Rs. 637 crores were largely driven by molecules in the commercial segment. Even though the revenues have declined this year, we continue to see good traction in business from a wider range of customers Our peptide investment plan is on track. We continue to garner more projects in this space which further validates our excitement about the opportunities that the segment holds. At an overall level, we have molecules in our portfolio which are currently at the take off stage, therefore we expect our growth trajectory to resume in FY26.” Result PDF
Conference Call with Neuland Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Neuland Laboratories announced Q3FY25 results Total Income: Rs 401.9 crore (1.8% growth YoY from Rs 394.9 crore). EBITDA: Rs 90.3 crore (decline of 26.4% YoY from Rs 122.7 crore). EBITDA Margin: 22.5% (decline of 860 bps YoY from 31.1%). PAT: Rs 101.4 crore (growth of 25.6% YoY from Rs 80.7 crore). PAT Margin: 25.2% (increase of 480 bps YoY from 20.4%). EPS (Basic): Rs 79.0 (growth of 25.6% YoY from Rs 62.9). Sucheth Davuluri, Vice-Chairman & Chief Executive Officer of the Company said: “We saw marginal topline growth this quarter as compared to Q3FY24. Nevertheless, these results align with our initial outlook at the start of the year regarding our expectations for FY25. We are steadily advancing our strategic initiatives and remain optimistic about achieving sustainable long-term growth through acquiring new customers, enhancing our expertise, expanding our capacity flexibly, and refining our processes.” Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “This quarter’s revenues were driven by several important molecules in the commercial CMS and GDS segments. We expect the recently commercialized molecules to scale even as we are on track to enhance our manufacturing capacity. There is good traction from our existing customers reverting for multiple projects as well as fresh interest from a range of new customeRs We are seeing increased interest in peptides leading to our recent decision to invest in a larger capacity. Overall, we are confident on the business momentum for the medium as well as long term.” Result PDF